Abstract

After a diagnosis of colorectal cancer (CRC), approximately 50% of patients will present distant metastasis. Although significant progress has been made in treatments, most of them will die from the disease. We investigated the predictive and prognostic potential of APC11, the catalytic subunit of APC/C, which has never been examined in the context of CRC. The expression of APC11 was assessed in CRC cell lines, in tissue microarrays (TMAs) and in public datasets. Overexpression of APC11 mRNA was associated with chromosomal instability, lymphovascular invasion and residual tumor. Regression models accounting for the effects of well-known protein markers highlighted association of APC11 protein expression with residual tumor (odds ratio: OR = 6.51; 95% confidence intervals: CI = 1.54–27.59; P = 0.012) and metastasis at diagnosis (OR = 3.87; 95% CI = 1.20–2.45; P = 0.024). Overexpression of APC11 protein was also associated with worse distant relapse-free survival (hazard ratio: HR = 2.60; 95% CI = 1.26–5.37; P = 0.01) and worse overall survival (HR = 2.69; 95% CI = 1.31–5.51; P = 0.007). APC11 overexpression in primary CRC thus represents a potentially novel theranostic marker of metastatic CRC.

Details

Title
Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer
Author
Drouet, Youenn 1 ; Treilleux, Isabelle 2 ; Viari, Alain 3 ; Léon, Sophie 2 ; Devouassoux-Shisheboran, Mojgan 4 ; Voirin, Nicolas 5 ; Christelle de la Fouchardière 6 ; Manship, Brigitte 6 ; Puisieux, Alain 7 ; Lasset, Christine 8 ; Moyret-Lalle, Caroline 7 

 Centre Léon Bérard, Département de Santé Publique, Lyon, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France 
 Centre Léon Bérard, Service d’Anatomopathologie, Lyon, France 
 INRIA Grenoble-Rhône-Alpes, 655 Avenue de l’Europe, Montbonnot, Saint Martin, France; Synergie Lyon Cancer, Plateforme de Bioinformatique ‘Gilles Thomas’ Centre Léon Bérard, Lyon, France 
 Centre Léon Bérard, Lyon, France; INSERM U1052, Cancer Research Center of Lyon, Lyon, France; CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon1, ISPB, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France 
 Centre Léon Bérard, Département de Santé Publique, Lyon, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d’Hygiéne, Epidémiologie et Prévention, Lyon, France 
 Centre Léon Bérard, Lyon, France 
 Centre Léon Bérard, Lyon, France; INSERM U1052, Cancer Research Center of Lyon, Lyon, France; CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon1, ISPB, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France 
 Centre Léon Bérard, Département de Santé Publique, Lyon, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France; Université de Lyon, Lyon, France 
Pages
1-14
Publication year
2018
Publication date
May 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2036770822
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.